A lack of toxicity of the AmBisome formulation was noted in both studies.
2
There were no breakthrough fungal infections during empirical therapy with AmBisome.
3
AmBisome followed a nonlinear dosage relationship that was consistent with reticuloendothelial uptake and redistribution.
4
The pharmacokinetic parameters of AmBisome were measured as those of amphotericin B by high-performance liquid chromatography.
5
AmBisome administered as a 1-h infusion in this population was well tolerated and was seldom associated with infusion-related toxicity.
1
We initiated intravenous administration of amphotercin B.
1
Time of treatment with Amph B was prolonged from 13 to 30 days and that with 5FC from 11 to 40 days.
1
High-dose liposomalamphotericinB was effective and safe in the treatment of neonatal candidiasis.
2
LiposomalamphotericinB is very effective and safe but currently unaffordable because of its high price.
3
This association of renal and hepatotoxicity with liposomalamphotericinB has not previously been reported in children.
4
LiposomalamphotericinB was always more active than the other drugs against all the microorganisms except C. bertholletiae.
5
Fungal eradication was more rapid in patients treated early with high doses and in patients who received high-dose liposomalamphotericinB as first-line therapy.
1
Similar combinations of NP-1 and amphotericinB, however, did not yield synergy.
2
Only amphotericinB was statistically superior to controls with regard to mortality.
3
However, data on agar-based tests for itraconazole and amphotericinB are yet scarce.
4
Treatment consisted in systemic amphotericinB combined with surgical debridement in 3 cases.
5
Large doses of amphotericinB are required for cure, causing significant renal toxicity.
1
Single-dose acute toxicity of the AmB microemulsion was studied on male albino Webster-derived CD-1 mice and compared with Fungizone.
Uso de abelcet em inglês
1
Elan shareholders have approved the sale of its anti-fungal drug Abelcet for $370 million at an egm held today.
2
Elan has won shareholder approval for the $370 million (€366.37 million) sale of the rights to its Abelcet treatment to US company Enzon.
3
Elan's asset sale to pay its huge debt grossed $370 million today with the disposal of an anti-fungal drug Abelcet for $370 million.